A halin yanzu, COVID-19 har yanzu yana cikin matsayin annoba a duniya. Babban matsayi na bambance-bambancen Delta da Omicron sun mamaye, yana haifar da ci gaba da haɓaka ikon watsa su. A cikin ci gaba da tashe-tashen hankula na COVID-19, baya ga rigakafin COVID-19, haɓaka ingantattun magungunan COVID-19 na baka da kuma hanyoyin gwaji masu sauri, masu sauƙi da sabbin abubuwa suma sun zama sabon buƙatu na rigakafin annoba da sarrafawa a halin yanzu. Viva Biotech Holdings XLement, wanda Viva BioInnovator ya saka hannun jari kuma ya haɓaka, sun himmatu wajen samar da magungunan COVID-19 na baka da gwajin ƙwayar cuta, suna ba da gudummawa ga yaƙi da cutar ta COVID-19.

Jan 2022, Pool Pool na Magunguna (MPP) ya ba da sanarwar cewa ya sanya hannu kan yarjejeniyoyin tare da kamfanoni masu masana'antu da yawa ciki har da Zhejiang Langhua Pharmaceutical Co., Ltd., reshen mallakar Viva Biotech hannun jari don kera maganin rigakafin cutar COVID-19 na baki da kuma molnupiravir. wadata a cikin 105 masu karamin karfi da matsakaici (LMICs) don sauƙaƙe damar shiga duniya mai arha don molnupiravir da tallafawa rigakafin cutar gida & sarrafawa. Kamfanoni biyar za su mayar da hankali wajen samar da danyen, kamfanoni 13 ne za su samar da danye da kuma na gamayya sannan kuma kamfanoni 9 za su samar da maganin da aka gama.

Kungiyar likitocin Patent Pool (MPP) wata kungiyar kiwon lafiyar jama'a ce mai samun goyon bayan Majalisar Dinkin Duniya da ke aiki don kara samun dama da saukaka hanyoyin samar da magunguna na ceton rai ga kasashe masu karamin karfi da matsakaicin kudin shiga. MPP da MSD, sunan kasuwanci na Merck & Co., Inc Kenilworth NJ Amurka sun rattaba hannu kan yarjejeniyar ba da lasisi na son rai a cikin Oktoba 2021. A karkashin sharuɗɗan yarjejeniyar, MPP, ta hanyar lasisin da MSD ta bayar, za a ba da izinin ƙara lasisin da ba keɓantacce ba. ba da lasisi ga masana'antun da rarraba tushen masana'anta don samar da ingantaccen ingantaccen molnupiravir zuwa ƙasashen da lasisin MPP ya rufe, ƙarƙashin ikon ƙa'ida na gida.

Molnupiravir (MK-4482 da EIDD-2801) wani bincike ne, wanda aka gudanar da baki nau'i ne na analog mai ƙarfi na ribonucleoside wanda ke hana kwafin SARS-CoV-2 (wakilin da ke haifar da COVID-19). Molnupiravir wanda MSD ke haɓakawa tare da haɗin gwiwa tare da Ridgeback Biotherapeutics, shine maganin rigakafi na baka na farko da ake samu don maganin COVID-19. Bayanai daga mataki na 3 MOVe-OUT sun nuna cewa farkon jiyya tare da molnupiravir ya rage haɗarin asibiti ko mutuwa cikin babban haɗari, manya waɗanda ba a yi musu allurar COVID-19 ba.

A cewar MPP, kamfanonin da aka ba da lasisin sun sami nasarar nuna ikon su na biyan buƙatun MPP da suka shafi ƙarfin samarwa, bin ka'ida, da kuma ikon cika ƙa'idodin ƙasashen duniya don ingantattun magunguna. Izinin da aka bai wa Langhua Pharmaceutical ta MPP yana wakiltar babban tabbaci da karɓuwa a cikin ci gaban tsarin sa da haɓaka APIs, dorewar wadata, tsarin GMP da EHS.

A ranar 2 ga Maris, 2022, Xlement, wani kamfani na NanoSPR biochip da kayan aikin biotech wanda a baya Viva BioInnovator ya saka hannun jari kuma ya samar da shi, ya sami sanarwar wucewa ta kimanta aikin daga Ma'aikatar Kimiyya da Fasaha ta Jamhuriyar Jama'ar Sin. Ayyukansa "R&D da Mass Production na NanoSPR COVID-19 Kit ɗin Gwajin Barbashi" yana ɗaya daga cikin mahimman ayyukan shirin "Rigakafin Rigakafin Kariya da Kula da Lafiyar Jama'a da Fasaha da Kayayyakin Amsar Gaggawa" wanda ke ba da muhimmin sashi ga maɓallin COVID-19- binciken kimiyya mai alaka da ke gudana a kasar Sin. Tare da nasarar wucewar sa zuwa binciken, Kit ɗin gwajin COVID-19 na Xlement shi ma ƙungiyar Tarayyar Turai CE ta sami ƙwararrun samarwa a nan gaba kuma za a yi amfani da shi nan ba da jimawa ba.

An yi amfani da fasahar guntu ta NanoSPR na musamman, Xlement ya haɓaka kayan gwajin don barbashi na COVID-19, wanda ke ba da damar gwajin mataki ɗaya na antigens da yawa don samfuran 96 a cikin mintuna 15, kuma hankalin yana kusa da gwada antigen guda ɗaya. Wannan hanyar tana nuna fa'idodi masu yawa idan aka kwatanta da dabarun gwajin gwajin nucleic acid na yanzu: ana iya amfani da shi don gwajin kai a gida, yana rage lokacin gwaji sosai, don haka, yana rage farashin gwajin reagents da aiki sosai. Tare da ƙarin karɓar fasahar NanoSPR a cikin gwajin COVID-19 wanda Xlement ya haɓaka, muna tsammanin ganin mafi dacewa ga ganewar asali nan take na samfuran da ake zargi da kuma saurin dubawa a kan-gizon a babban sikelin.

ABUBUWAN DA ZA KU GUDU DAGA WANNAN LABARI:

A ranar 2 ga Maris, 2022, Xlement, wani kamfani na NanoSPR biochip da kayan aikin biotech wanda a baya Viva BioInnovator ya saka hannun jari kuma ya samar da shi, ya sami sanarwar wucewa ta kimanta aikin daga Ma'aikatar Kimiyya da Fasaha ta Jamhuriyar Jama'ar Sin.
A karkashin sharuɗɗan yarjejeniyar, MPP, ta hanyar lasisin da MSD ta bayar, za a ba da izini don ƙara lasisi mara izini ga masana'antun da kuma rarraba tushen masana'anta don samar da ingantaccen molnupiravir ga ƙasashen da lasisin MPP ya rufe, batun. zuwa izinin tsari na gida.
A cikin ci gaba da tashe-tashen hankula na COVID-19, ban da rigakafin COVID-19, haɓaka ingantattun magungunan COVID-19 na baka da kuma hanyoyin gwaji masu sauri, masu sauƙi da sabbin abubuwa suma sun zama sabon buƙatu na rigakafi da sarrafa cutar ta yanzu.